biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > New Questions

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jun 09, 2023 2:52pm

86 Views

Post# 35488992

RE:RE:New Questions

Well, a LinkedIn post! What better evidence would one want?

Like the rest of us, poof doesn't know whether the J&J deal expired or not. But he's taking his best shot at it, a LinkedIn post that has the same value as a Stockhouse post.

If the J&J deal was renewed or extended, and that event wasn't revealed, then it's another example of Rathjen ensuring that xB3 wasn't getting any good publicity.

I thought that not even you, poof, would walk barefooted into that little dollop of poo.

jd

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale